Different approaches targeting Gp-100 as an antigen for the treatment of melanoma have been developed, including Gp-100-based vaccines, mRNA electroporated dendritic cells, and a fusion protein denominated IMCGp-100, or tebentafusp. The gene discussed is PMEL; the disease is melanoma.